From prediction to clinical decision-making: Explainable machine learning in acute suppurative cholecystitis

Abstract

Acute suppurative cholecystitis is a severe and potentially life-threatening form of gallbladder inflammation, in which delayed diagnosis and intervention are associated with increased morbidity and perioperative risk. Early differentiation from uncomplicated disease remains challenging, as clinical presentation and conventional imaging often fail to accurately reflect disease severity at initial assessment. Recent advances in machine learning, particularly the integration of clinical data with computed tomography-derived radiomic features, have improved preoperative risk stratification by capturing complex, high-dimensional patterns beyond traditional diagnostic frameworks. However, clinical adoption has been limited by concerns regarding interpretability and trust. Explainable machine learning addresses this limitation by providing transparent insights into model predictions. Techniques such as SHapley Additive exPlanations enable quantification of feature contributions at both population and individual levels, supporting clinical understanding and facilitating integration into decision-making. In this Opinion Review, we argue that the value of explainable machine learning lies not only in prediction, but in structuring clinical decision-making. Interpretable models may enhance early risk recognition, guide surgical timing, and improve multidisciplinary coordination. Future research should focus on prospective validation, workflow integration, and evaluation of real-world clinical impact.

Key Words: Acute suppurative cholecystitis; Explainable machine learning; Clinical decision-making; Radiomics; Surgical prioritization; Perioperative care

Core Tip: Early and accurate identification of acute suppurative cholecystitis is essential for timely surgical intervention and improved outcomes. Explainable machine learning models that integrate clinical and radiomic data provide transparent risk stratification, supporting surgical decision-making and perioperative prioritization. When embedded into multidisciplinary care pathways, such tools may enhance patient safety and real-world management of acute biliary disease.

INTRODUCTION

Acute suppurative cholecystitis represents a severe and potentially life-threatening progression of gallbladder inflammation, frequently associated with systemic inflammatory response, rapid clinical deterioration, and increased perioperative risk[1,2]. Delayed diagnosis or postponed surgical intervention has been consistently linked to higher complication rates, prolonged hospitalization, and worse overall outcomes[1,3,4].

Despite advances in diagnostic imaging and perioperative care, early differentiation between uncomplicated and suppurative disease remains challenging in routine clinical practice. Clinical presentation may be nonspecific, while conventional imaging findings often fail to reliably distinguish disease severity at initial evaluation[2,5]. As a result, uncertainty in early risk assessment may lead either to delayed surgical escalation or to unnecessary intervention in lower-risk patients[6,7].

Recent studies across radiomics and surgical artificial intelligence (AI) consistently demonstrate that existing clinical scoring systems provide structured approaches to severity assessment; however, they rely on predefined variables and fixed weighting schemes that may not fully capture the complexity of disease progression[2,7]. In particular, these tools may inadequately reflect subtle imaging characteristics or nonlinear interactions between clinical and radiological parameters that influence the development of suppuration[2,5].

In recent years, machine learning approaches have emerged as promising tools for improving risk stratification in acute biliary disease. The integration of clinical data with computed tomography (CT)-derived radiomic features enables the extraction of high-dimensional quantitative information that extends beyond conventional visual interpretation[8-10]. These models offer the potential to identify patterns associated with disease severity and operative complexity that may not be readily apparent using traditional methods[9,10].

However, the clinical implementation of such predictive models has been limited by concerns regarding interpretability and trust. Many machine learning systems operate as “black-box” models, providing limited insight into how predictions are generated, thereby restricting their acceptance in high-stakes clinical environments[11,12]. Explainable machine learning addresses this limitation by enabling transparent interpretation of model outputs, allowing clinicians to understand how specific features contribute to predicted risk[13,14]. This transition from opaque prediction to interpretable decision support represents a critical step toward the integration of AI into real-world surgical decision-making[11,15].

However, beyond predictive performance, an important limitation of many machine learning applications in acute care settings is their limited integration into real-world clinical workflows. High-performing models developed in retrospective datasets often fail to translate into clinical practice due to a lack of external validation, variability in imaging acquisition, and differences in patient populations across institutions[16,17]. In the context of acute biliary disease, where clinical decisions are time-sensitive and resource-dependent, the utility of predictive models is closely linked not only to their accuracy but also to their robustness, generalizability, and compatibility with existing diagnostic pathways. These translational gaps highlight the need for models that are not only predictive but also clinically interpretable and operationally feasible.

The central limitation in acute suppurative cholecystitis is not the absence of data, but the inability to translate available information into timely and defensible decisions. In this context, AI should not be viewed as a diagnostic adjunct, but as a decision-structuring tool.

ACUTE SUPPURATIVE CHOLECYSTITIS AS A CLINICAL DECISION-MAKING PROBLEM

Acute suppurative cholecystitis represents not only a diagnostic entity but, more importantly, a time-sensitive clinical decision-making challenge. In the acute care setting, the critical question extends beyond the presence of inflammation to determining which patients require urgent surgical intervention, intensified monitoring, or temporizing management strategies. This distinction is particularly complex in patients presenting with intermediate clinical severity, where clear indicators of disease progression may be absent[1,2,7].

The timing of surgical intervention remains a central determinant of clinical outcomes. Multiple studies have demonstrated that early laparoscopic cholecystectomy is associated with reduced complication rates, shorter hospital stay, and improved overall outcomes, whereas delayed intervention may result in disease progression, increased operative difficulty, and higher perioperative morbidity[3,18,19]. Despite this evidence, real-world practice frequently deviates from early operative management due to uncertainty in risk stratification and concerns regarding operative safety, particularly in patients with significant comorbidity burden.

Clinical uncertainty is further amplified by limitations in both presentation and imaging. Patients may exhibit nonspecific or moderate symptoms, while conventional imaging modalities may fail to reliably distinguish between uncomplicated inflammation and early suppuration. This diagnostic ambiguity complicates risk assessment and may delay appropriate escalation of care[5,20]. In addition, variability in imaging interpretation and institutional practices contributes to inconsistency in clinical decision-making across healthcare settings.

The limitations of current assessment strategies are also reflected in existing clinical scoring systems. Although guideline-based frameworks provide structured approaches to severity grading, they rely on predefined variables and fixed weighting schemes that may not adequately capture the complex and dynamic nature of disease progression[2,7,21]. In particular, these systems may fail to incorporate subtle imaging features or nonlinear interactions between clinical and radiological parameters that influence the development of suppurative disease.

The consequences of this uncertainty are clinically significant and bidirectional. Underestimation of disease severity may result in delayed surgical intervention, increasing the risk of complications such as gallbladder perforation, sepsis, or conversion to open surgery. Conversely, overestimation of risk may lead to unnecessary early intervention in patients who could be safely managed with short-term optimization[22,23]. This dual risk highlights the need for more precise, individualized approaches to early risk stratification in acute suppurative cholecystitis.

LIMITATIONS OF CONVENTIONAL ASSESSMENT STRATEGIES

Conventional approaches to the assessment of acute cholecystitis rely on a combination of clinical evaluation, laboratory findings, and imaging studies. While these components form the basis of current diagnostic pathways, their ability to accurately stratify disease severity-particularly in the early stages of suppurative progression-remains inherently limited. This limitation is not merely a matter of diagnostic sensitivity, but reflects a fundamental inability to capture the dynamic and heterogeneous nature of inflammatory progression in acute biliary disease[24].

Clinical assessment is frequently constrained by nonspecific presentation and inter-patient variability. Symptoms such as right upper quadrant pain, fever, and leukocytosis may be present across a broad spectrum of disease severity, while elderly or immunocompromised patients may exhibit attenuated or atypical clinical responses. As a result, reliance on clinical parameters alone may obscure early progression to suppurative disease, particularly in patients with competing comorbidities[25].

Similarly, conventional imaging-primarily ultrasonography and CT-plays a central role in diagnosis but demonstrates important limitations in severity discrimination. While imaging findings such as gallbladder wall thickening, pericholecystic fluid, and distension are useful indicators of inflammation, they lack specificity for suppuration and may overlap between uncomplicated and complicated disease states[25,26]. Furthermore, qualitative interpretation of imaging is inherently operator-dependent and subject to interobserver variability, which may further reduce diagnostic consistency across institutions[27].

Existing clinical scoring systems and guideline-based severity classifications attempt to standardize assessment; however, they rely on predefined variables and linear weighting schemes that may not adequately reflect the complex interactions underlying disease progression. In particular, these models are limited in their ability to incorporate high-dimensional imaging features or to account for nonlinear relationships between clinical, laboratory, and radiological parameters[7,28]. This structural limitation restricts their capacity to provide individualized risk estimation in heterogeneous patient populations.

The progression from uncomplicated inflammation to suppurative cholecystitis is not a binary event but a dynamic process influenced by multiple interacting factors, including local ischemia, bacterial proliferation, host inflammatory response, and timing of intervention. Conventional assessment strategies, which are largely static and threshold-based, are poorly suited to capturing these evolving pathophysiological trajectories[29,30].

These limitations highlight a critical gap between available diagnostic tools and the clinical need for early, precise, and individualized risk stratification. Addressing this gap requires approaches capable of integrating multidimensional data and modeling complex interactions in a manner that reflects real-world disease behavior.

RADIOMICS AND MACHINE LEARNING IN ACUTE BILIARY DISEASE

Radiomics and machine learning have emerged as promising tools for refining risk assessment in acute biliary disease because they can transform routine imaging into quantitative, high-dimensional data that extend beyond conventional visual interpretation. Rather than relying solely on descriptive CT findings, radiomics enables systematic extraction of intensity, texture, and spatial heterogeneity features that may capture inflammatory severity more precisely than standard reporting. Recent methodological reviews emphasize that the radiomics pipeline is not simply “feature extraction”, but a multistep process involving image acquisition, segmentation, preprocessing, feature selection, model training, and validation, each of which directly affects downstream performance and clinical credibility[31].

Within acute care imaging, the attraction of machine learning lies in its ability to model nonlinear interactions between variables that conventional scoring approaches tend to treat in isolation. This is particularly relevant in biliary disease, where laboratory values, clinical presentation, and CT-derived inflammatory patterns may interact in ways that are difficult to capture through threshold-based assessment alone. Although direct literature specifically focused on acute suppurative cholecystitis remains limited, adjacent biliary imaging studies already show the practical direction of the field. This limitation does not diminish the clinical relevance of the approach, but rather reflects the early stage of disease-specific model development. Evidence from adjacent acute biliary conditions, including gallstone pancreatitis and complicated cholecystitis, demonstrates consistent feasibility of integrating radiomic and clinical data for severity prediction, supporting the translational plausibility of similar approaches in suppurative disease. For example, a 2024 study in acute gallstone pancreatitis combined CT features with machine learning to predict severity, used calibration and decision-curve analysis, and incorporated SHapley Additive exPlanations (SHAP)-based interpretation, illustrating how multimodal imaging-driven models can be translated into clinically usable prediction frameworks in urgent biliary disease[32-34].

The conceptual value of radiomics in this setting is therefore twofold. First, it offers a mechanism for recovering imaging information that may be visually underappreciated, particularly when inflammatory change is subtle, heterogeneous, or evolving. Second, it creates a bridge between radiological phenotype and individualized risk estimation[35]. However, this promise should not be overstated. Radiomics datasets are typically high-dimensional, often contain more features than samples, and are vulnerable to instability introduced by acquisition parameters, segmentation choices, and statistical overfitting. These are not secondary technical details; they are central determinants of whether a model remains biologically meaningful and clinically reproducible[31,36].

For this reason, the strongest radiomics-based machine learning studies are not those that merely report high discrimination, but those that demonstrate methodological discipline and translational intent. Recent reviews stress the importance of robust preprocessing, transparent validation strategy, and quality-assessment frameworks for radiomics studies, because model performance without reproducibility has limited clinical value[31,37]. In parallel, broader surgical AI evidence shows that most current models remain concentrated in preoperative risk assessment, yet validation quality is frequently suboptimal and external validation is still lacking in a large proportion of studies. This is highly relevant to acute suppurative cholecystitis, where any prediction model intended to influence operative prioritization must be trusted not only statistically but operationally[38] (Table 1).

Table 1 Summary of recent studies on machine learning and radiomics in acute biliary disease and surgical risk prediction.

Ref.	Year	Population	Modality	Model	Key findings	Translational value	Limitations	Gap identified
Demircioğlu[31]	2025	Radiomics methods	Imaging	ML frameworks	Reproducibility critical	High	Pipeline variability	No clinical translation
Ma et al[32]	2024	Acute biliary disease	CT radiomics	XGBoost + SHAP	Interpretable early severity prediction	High	Single-center	Lack of validation in cholecystitis-specific cohorts
Kenig et al[38]	2024	Surgical AI	Mixed	ML models	Improved preoperative prediction	Moderate	Limited validation	Lack of explainability integration
Cè et al[37]	2024	Radiomics workflow	CT/MRI	ML pipelines	Importance of pipeline standardization	High	Variability	No direct clinical application
Teng et al[36]	2024	Radiomics	Imaging	ML models	Focus on clinical integration challenges	High	Limited deployment	Lack of real-time decision tools
Sadeghi et al[40]	2024	Healthcare AI	Mixed	XAI models	Explainability improves trust	High	Misinterpretation risk	Limited disease-specific application
Borys et al[41]	2023	Imaging AI	Imaging	SHAP/XAI	Enables patient-level interpretation	High	Needs validation	Not integrated in surgical workflows
Erickson et al[9]	2019	Imaging review	Multimodal	ML overview	Highlights ML potential	Low-Moderate	Conceptual only	No clinical implementation
Bi et al[10]	2019	Imaging datasets	CT radiomics	ML classifiers	Quantifies imaging heterogeneity	Moderate	Feature instability	No integration with clinical variables
Hosny et al[8]	2018	Imaging datasets	CT radiomics	Deep learning	Demonstrates scalability	Moderate	Generalizability issues	Not tailored to acute surgical decision-making

SHAP: SHapley Additive exPlanations; CT: Computed tomography; ML: Machine learning; MRI: Magnetic resonance imaging; XAI: Explainable Artificial Intelligence; AI: Artificial intelligence; XGBoost: Extreme Gradient Boosting.

Radiomics and machine learning provide a clinically plausible pathway for moving from descriptive imaging toward individualized preoperative risk stratification in acute biliary disease. Their real value, however, depends on more than predictive accuracy alone. A useful model in acute suppurative cholecystitis must be reproducible, externally valid, and compatible with urgent surgical workflows[39]. These requirements make explainability not an optional add-on, but the necessary next step in converting radiomics-based prediction into clinically defensible decision support. This model provides a practical bridge between computational prediction and bedside decision-making.

FROM PREDICTION TO DECISION: A CLINICAL TRANSLATION FRAMEWORK

We propose a three-layer framework for integrating explainable machine learning into acute biliary care: (1) Prediction layer: Integration of clinical and radiomic data for individualized risk estimation; (2) Explanation layer: Identification of feature-level contributions using explainability methods such as SHAP; and (3) Decision layer: Translation of interpreted outputs into clinical actions, including surgical prioritization, monitoring intensity, and perioperative planning (Figure 1). This framework emphasizes that prediction alone is insufficient; clinical value emerges only when model outputs are interpretable and directly linked to actionable decisions.

Figure 1 Integration of explainable machine learning into clinical decision-making in acute suppurative cholecystitis. Clinical and imaging data are combined through radiomic feature extraction and integrated into a machine learning model. Explainability methods, such as SHapley Additive exPlanations, provide both global and patient-specific interpretation of model predictions. These outputs support risk stratification and guide clinical decision-making, including surgical prioritization and perioperative management. Multidisciplinary team involvement ensures that predictions are translated into coordinated clinical action, while outcome feedback enables continuous model refinement. SHAP: SHapley Additive exPlanations; CT: Computed tomography; AI: Artificial intelligence.

EXPLAINABLE MACHINE LEARNING: FROM BLACK BOX TO CLINICALLY DEFENSIBLE SUPPORT

The principal barrier to the clinical adoption of machine learning in acute surgical settings is not solely model performance, but lack of interpretability. In time-sensitive conditions such as acute suppurative cholecystitis, where decisions regarding surgical prioritization and perioperative management must often be made under uncertainty, prediction without explanation is of limited clinical value. Recent reviews in healthcare artificial intelligence consistently emphasize that explainability is not an optional feature, but a prerequisite for safe and responsible clinical implementation[40-42].

From a clinical perspective, explainable machine learning becomes meaningful only when it addresses specific decision-relevant questions: Which variables drive the prediction, how strongly they influence risk, and whether this influence is consistent across the population or specific to an individual patient. SHAP has emerged as one of the most widely applied approaches in this context, precisely because it provides both global and local interpretability. At the population level, SHAP enables ranking of features based on their average contribution to model output, whereas at the individual level, it allows decomposition of a single prediction into feature-specific contributions[41,43].

In the context of acute suppurative cholecystitis, this dual-level interpretability has direct clinical implications. A model that identifies a patient as high risk becomes clinically actionable only if it also indicates whether this prediction is driven by radiomic indicators of tissue heterogeneity, attenuation-related features, laboratory markers of inflammation, or combined effects. Without such information, predicted probabilities remain disconnected from pathophysiological reasoning. With explainability, however, predictions become auditable. Radiologists can assess whether image-derived features are anatomically plausible, surgeons can evaluate whether predicted severity aligns with intraoperative expectations, and perioperative teams can determine whether the model output justifies earlier escalation of care[44,45].

Explainability does not equate to correctness. SHAP and related techniques explain how a model arrives at a prediction, but they do not guarantee that the underlying associations are clinically valid. Features may appear influential due to confounding, data imbalance, or site-specific artifacts rather than true biological relevance. Recent critical analyses of explainable AI highlight the risk of “explanation bias”, whereby clinicians may over-trust interpretable outputs without sufficient validation of model robustness and generalizability[40,42]. This distinction is particularly relevant in acute care, where incorrect but plausible explanations may still lead to inappropriate clinical decisions.

Furthermore, the utility of explainability is not solely determined by the algorithm, but also by how explanations are presented to end users. Emerging evidence suggests that different explanation formats-such as SHAP visualizations vs simplified clinician-oriented summaries-may lead to different levels of trust, usability, and decision impact[30,46]. In urgent surgical environments, where cognitive load is high and time is limited, explanations must be both technically accurate and clinically interpretable in a rapid, intuitive manner. A non-interpretable high-performing model is clinically less valuable than a slightly less accurate but explainable model that can be interrogated and contextualized within real-world decision-making. Feature attribution methods describe model behavior, but do not confirm causal relationships, and therefore must be interpreted within the context of clinical knowledge and external validation.

Explainable machine learning should be understood as the critical translational layer that determines whether predictive models can be meaningfully integrated into clinical workflows. In acute suppurative cholecystitis, its value lies not in enhancing algorithmic transparency per se, but in enabling clinicians to interrogate, contextualize, and selectively trust model outputs in situations where decision-making carries immediate operative consequences[47].

CLINICAL IMPLICATIONS: SURGICAL PRIORITIZATION AND PERIOPERATIVE DECISION-MAKING

The relevance of predictive modeling in acute suppurative cholecystitis is determined not by discrimination metrics, but by its capacity to alter real-time clinical decisions. A model that does not influence operative timing, monitoring strategy, or resource allocation has limited clinical value, regardless of statistical performance.

One of the most critical decision points in acute biliary disease is the timing of surgical intervention. While early laparoscopic cholecystectomy is generally associated with improved outcomes, including reduced complications and shorter hospital stay, clinicians frequently encounter patients in whom operative timing remains uncertain due to comorbidities, equivocal imaging findings, or intermediate disease severity[48-50]. In such cases, predictive models may provide an additional layer of risk assessment, helping to identify patients who would benefit from early operative escalation despite initially inconclusive findings.

The clinical utility of these models is maximized when predictions can be interpreted within a decision framework rather than as isolated probabilities. For example, a high predicted risk of suppurative disease may justify prioritization for early surgery, intensified perioperative monitoring, or involvement of more experienced surgical teams. Conversely, lower-risk predictions may support short-term optimization, antibiotic therapy, or delayed intervention in selected patients. This scenario-based application aligns predictive modeling with real-world clinical workflows and enhances its practical relevance[6,7].

Beyond surgical timing, predictive models may also influence perioperative risk management. Patients identified as high risk may require more aggressive hemodynamic monitoring, earlier anesthetic evaluation, or preparation for potential intraoperative complications such as conversion to open surgery. In this context, prediction becomes not only a tool for deciding “when to operate,” but also for anticipating “how to operate” and “under what level of risk”[2,50].

However, the integration of predictive models into clinical decision-making must be approached with caution. Over-reliance on model outputs without appropriate clinical contextualization may lead to premature or unnecessary intervention, while underutilization may negate potential benefits. The optimal use of predictive tools therefore lies in their incorporation as decision-support systems that augment, rather than replace, clinician judgment. This balance is particularly important in acute suppurative cholecystitis, where decisions are often made under time pressure and with incomplete information[6,48].

The clinical impact of machine learning in this setting depends on its ability to reduce uncertainty at critical decision points. By supporting more precise and individualized risk stratification, predictive models have the potential to align surgical timing, perioperative planning, and resource utilization with the underlying severity of disease, thereby improving both patient outcomes and system efficiency.

MULTIDISCIPLINARY INTEGRATION IN ACUTE BILIARY CARE

The integration of predictive modeling into acute suppurative cholecystitis is inherently multidisciplinary, as its clinical value depends on how model outputs are interpreted and acted upon across different professional roles. In acute surgical care, decision-making is distributed rather than centralized, and therefore the impact of machine learning is determined not only by predictive accuracy but by how effectively information is translated into coordinated clinical action[29,51] (Table 2).

Table 2 Clinical decision framework integrating explainable machine learning in acute suppurative cholecystitis.

Risk level (ML output)	Explainability insight (SHAP)	Clinical interpretation	Recommended action	Multidisciplinary involvement
High risk	Strong contribution from radiomic heterogeneity-inflammatory markers	Likely suppurative cholecystitis with high operative complexity	Early laparoscopic cholecystectomy; prioritize OR scheduling; consider senior surgical team	Surgeon, anesthesiologist, radiologist, ICU team
Intermediate risk	Mixed feature contribution; moderate radiomic signal with variable clinical parameters	Uncertain progression; potential for deterioration	Close monitoring; repeat imaging; optimize comorbidities; reassess within 12-24 hours	Surgeon, radiologist, ward team
Low risk	Minimal radiomic heterogeneity; low inflammatory contribution	Likely uncomplicated disease	Conservative management; antibiotics; delayed surgery if indicated	Surgeon, ward team
High risk with discordant clinical findings	High radiomic signal but mild clinical presentation	Early-stage suppuration or subclinical progression	Escalate monitoring; consider early intervention despite mild symptoms	Surgeon, radiologist
Low risk with severe clinical presentation	Low radiomic signal but strong clinical/Lab abnormalities	Possible alternative diagnosis or false-negative model output	Re-evaluate diagnosis; additional imaging; do not rely solely on model	Full team

SHAP: SHapley Additive exPlanations; ML: Machine learning; ICU: Intensive care unit; OR: Operating room.

From a surgical perspective, risk stratification primarily informs operative prioritization and technical planning. Surgeons are required to balance the risks of early intervention against the potential consequences of disease progression, often in the setting of incomplete information. Explainable model outputs may support this process by identifying patients at higher risk of suppuration or operative difficulty, thereby justifying earlier surgical escalation or allocation of more experienced surgical teams. This shifts decision-making from reactive to anticipatory, allowing operative planning to be aligned more closely with predicted disease severity[30,52].

For radiologists, the introduction of radiomics-based models alters the role of imaging from descriptive reporting to quantitative risk contribution. Rather than serving solely as interpreters of imaging findings, radiologists become critical evaluators of model validity, particularly in assessing whether extracted features and their attributed importance are anatomically and clinically plausible. This interpretive feedback loop is essential for maintaining trust in model outputs and ensuring that imaging-derived predictions are not driven by artifacts or non-reproducible patterns[53,54].

Anesthesiologists contribute a parallel dimension of risk assessment focused on perioperative physiology and procedural safety. In patients identified as high risk, predictive models may support earlier anesthetic evaluation, optimization of comorbidities, and planning for intraoperative instability or postoperative critical care requirements. This is particularly relevant in acute biliary disease, where systemic inflammation and sepsis risk may significantly influence anesthetic management and postoperative outcomes[55,56].

Nursing teams play a central role in continuous patient monitoring and early detection of clinical deterioration. Integration of risk predictions into ward-level workflows may allow targeted monitoring strategies, prioritization of high-risk patients, and earlier escalation of care when subtle changes occur. In this context, predictive outputs become operational tools that support vigilance and responsiveness, rather than abstract risk indicators[57,58].

At the system level, multidisciplinary integration extends to coordination of operating room scheduling, resource allocation, and patient flow. Predictive stratification may support prioritization of surgical cases, optimization of bed utilization, and more efficient deployment of personnel in high-demand acute care environments. However, successful implementation requires alignment between technological outputs and institutional workflows, as well as clear communication pathways between specialties[29,30].

The effectiveness of machine learning in acute suppurative cholecystitis is determined by its ability to function within this multidisciplinary ecosystem. Predictive models that fail to translate into coordinated action across clinical roles are unlikely to influence outcomes. Conversely, when integrated appropriately, explainable machine learning has the potential to enhance shared decision-making, reduce uncertainty, and improve the alignment between predicted risk and clinical intervention.

For clinical implementation, explainable machine learning models must be embedded within existing hospital information systems and imaging workflows, allowing automated extraction of relevant features and real-time risk estimation at the point of care. Decision support outputs should be integrated into routine clinical interfaces, such as radiology reports or electronic health records, to ensure accessibility without additional workflow burden.

IMPLEMENTATION CHALLENGES AND REAL-WORLD BARRIERS

The translation of machine learning models from experimental settings to real-world clinical practice remains a major unresolved challenge. While predictive performance is often emphasized in model development, successful implementation in acute care environments requires a broader set of conditions, including reproducibility, interoperability, and alignment with clinical workflows. In acute suppurative cholecystitis, where decisions are time-sensitive and resource-dependent, these challenges are particularly pronounced[17,59].

The primary barrier to clinical adoption is not algorithmic performance, but failure of integration into real-world workflows. One of the most significant barriers is the lack of external validation and generalizability. Many predictive models are developed using retrospective, single-center datasets, which may not reflect variability in patient populations, imaging protocols, or institutional practices. As a result, model performance often declines when applied outside the original development setting, limiting clinical reliability[16,60]. This issue is especially relevant for radiomics-based models, where variations in image acquisition parameters and segmentation techniques can substantially alter feature stability.

Data heterogeneity represents an additional layer of complexity. Differences in scanner technology, imaging protocols, and reconstruction algorithms can lead to variability in radiomic features, raising concerns about reproducibility across centers. Without standardized acquisition and preprocessing pipelines, the same model may generate inconsistent outputs for similar clinical cases, undermining clinician trust and limiting scalability[22,61].

Integration into clinical workflows is another critical barrier. In acute surgical settings, decision-making processes are rapid, iterative, and often non-linear. Predictive models that require additional data processing steps, manual segmentation, or complex interpretation may not be feasible in time-constrained environments. Therefore, implementation success depends not only on model accuracy but also on usability, speed, and seamless integration into existing clinical systems such as electronic health records[12,17].

Regulatory and ethical considerations further complicate adoption. The use of machine learning in clinical decision-making raises questions regarding accountability, transparency, and bias. Models trained on non-representative datasets may inadvertently encode systemic biases, leading to unequal performance across patient subgroups. Addressing these issues requires not only technical validation but also governance frameworks that ensure safe and equitable use of artificial intelligence in healthcare[59,60].

Clinician acceptance remains a decisive factor. Even well-validated models may fail to influence practice if they are perceived as unreliable, non-transparent, or disruptive to established workflows. Trust is built not only through performance metrics but through consistency, interpretability, and demonstrable clinical benefit. In this context, explainability becomes directly linked to implementation success, as it allows clinicians to evaluate whether model outputs are credible and relevant to individual patient scenarios[12,62].

These barriers highlight that the primary challenge is not the development of predictive models, but their translation into clinically usable tools. Overcoming these limitations requires coordinated efforts in standardization, validation, workflow integration, and clinician engagement. Only under these conditions can machine learning move from theoretical promise to practical impact in acute suppurative cholecystitis.

CONCLUSION

Acute suppurative cholecystitis exemplifies a clinical scenario in which decision-making must occur under uncertainty, yet carries immediate operative consequences. Conventional assessment strategies-while essential-remain limited in their ability to provide early, individualized risk stratification, particularly in patients with intermediate or evolving disease. This gap is not merely diagnostic, but decisional, directly influencing the timing of intervention and perioperative outcomes. The integration of radiomics and machine learning offers a pathway toward more refined risk estimation by capturing complex, multidimensional patterns that extend beyond traditional clinical and imaging assessment. However, predictive performance alone is insufficient to support clinical adoption. Without interpretability, such models remain disconnected from real-world decision-making processes.

Explainable machine learning represents the critical link between prediction and action. By enabling transparent, patient-specific interpretation of model outputs, it allows clinicians to evaluate, contextualize, and selectively trust predictions within the framework of clinical judgment. In this sense, the value of artificial intelligence in acute biliary disease lies not in replacing decision-making, but in structuring it-transforming fragmented clinical information into coherent, actionable insight.

The impact of these technologies is inherently dependent on their integration into multidisciplinary workflows. Surgical prioritization, anesthetic planning, radiological validation, and ward-level monitoring must operate in coordination, with predictive outputs informing-not dictating-clinical decisions across these domains. Without such integration, even the most accurate models are unlikely to influence outcomes.

Explainable machine learning redefines the role of artificial intelligence in acute biliary disease-from prediction toward accountable decision support. Its clinical impact will not be determined by algorithmic sophistication alone, but by its ability to reduce uncertainty at critical decision points and align multidisciplinary action with individualized risk.